Abstract

PurposeThis ex vivo study aimed to develop and evaluate a novel cylinder bioprosthetic valve for mitral and tricuspid valve replacements, addressing concerns related to valve size, anticoagulation, and postoperative morbidity. DescriptionExisting bioprosthetic valves lack annulus–papillary muscle continuity. In contrast, our valve, which is crafted from autologous pericardium, maintains annulus–papillary muscle continuity, maximizes the orifice area when open, and closes in response to rising ventricular pressure, thus preserving mitral valve complexity. It also offers a comprehensive size range: implanted mitral valve diameters ranged from 13 to 26 mm, and implanted tricuspid valve diameters ranged from 15 to 28 mm. EvaluationAnimal models demonstrated satisfactory coaptation lengths and excellent valve performance without regurgitation. ConclusionsOur newly designed valve is a geometrically adaptable alternative to existing valves. Its autologous pericardium construction, open design position, and preservation of annulus–papillary muscle continuity address key limitations in existing implants. Moreover, with a broad size selection, this valve accommodates patients across all age groups. The innovative design and potential clinical benefits make this valve a breakthrough in atrioventricular valve replacement.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call